Sai Parenterals Reports Strong Q1 FY27 Results as Company Varies IPO Proceeds for Strategic Acquisitions

Sai Parenterals Reports Strong Q1 FY27 Results as Company Varies IPO Proceeds for Strategic Acquisitions​

Sai Parenterals Limited has announced its un-audited financial results for the quarter ended June 30, 2026, showing robust consolidated and standalone growth. The company is also detailing strategic shifts in the use of IPO proceeds, directing funds towards majority stakes in two new operating pharmaceutical assets and advancing international capacity expansion.

The integrated, IP-led pharmaceutical enterprise operates across contract development and manufacturing for multinational customers and branded generic formulations sold domestically and exported globally.

Key Consolidated Financial Highlights​

For the quarter ended June 30, 2026, consolidated revenue stood at Rs. 182.4 crore, marking a significant increase from Q1 FY26. The gross profit recorded was Rs. 76.2 crore, achieving a Gross Profit Margin of 41.8%.

Consolidated EBITDA reached Rs. 27.3 crore, representing an EBITDA margin of 14.9%, which is an improvement of 50 basis points (bps) over the 14.4% recorded in Q4 FY26. Profit After Tax (PAT) was reported at Rs. 7.9 crore, achieving a PAT margin of 4.3%.

The company noted that the consolidated figures for Q1 FY27 include a full quarter of Noumed Pharmaceuticals; accordingly, year-on-year comparisons are not strictly like-for-like. While margins improved, the management pointed out that recovery from raw material cost increases remains partial as contractual agreements provide customers a 90-day window before price revisions take effect. Furthermore, absorbing elevated air-freight costs arising from industry-wide shipping disruption in Australia impacted the quarter's profitability.

The performance breakdown for the consolidated entity is detailed below:


The company also noted that the standalone entity contributed 31% of consolidated revenue but secured 61% of consolidated EBITDA, reflecting the current operating status of the Noumed platform pending in-house manufacturing and volume internalisation in Adelaide.

Standalone Performance and Strategic Investments​

On a standalone basis, Sai Parenterals reported robust growth, with Total Revenue reaching Rs. 56.2 crore, compared to Q1 FY26 revenue of Rs. 20.4 crore. This represents a year-on-year growth of 174.8%. Gross Profit stood at Rs. 22.1 crore, and EBITDA reached Rs. 16.8 crore—a 292.7% increase from the Rs. 4.3 crore in Q1 FY26. The standalone EBITDA margin was 29.8%, marking an 890 basis point expansion year-on-year due to operating leverage. Profit After Tax (PAT) stood at Rs. 8.9 crore, demonstrating a 975.1% growth compared to the Q1 FY26 PAT of Rs. 0.8 crore.

The company has announced two major strategic investments and provided updates on international projects:

Acquisitions for Research and Capacity:
The Board approved deploying funds through a variation in IPO proceeds to acquire majority stakes in two operational pharmaceutical assets.
1. Saicriti Pharma Private Limited: Sai Parenterals plans to acquire a 60% equity stake in Saicriti Pharma Private Limited for Rs. 83.83 crore. Saicriti is constructing a critical-care injectable facility at Gummadidala, designed to EU-GMP and USFDA standards, with capability in complex injectables and lyophilisation. The total project cost is estimated at Rs. 215 crore; the Company's contribution remains Rs. 83.83 crore. This route yields approximately 154.66 million units of injectable capacity against 105 million planned under the original upgradation plan, with completion extended to April 2027.
2. Prathyak Laboratories Private Limited: SP Analytics Private Limited (the dedicated R&D subsidiary) proposes acquiring a 60% equity stake in Prathyak Laboratories for Rs. 18.02 crore. Prathyak operates an established R&D centre in Genome Valley, possessing three years of operation, 65 personnel including 28 research scientists, and a pipeline of 150 SKUs across 86 molecules. The transaction is expected to complete on or before September 30, 2026.

Global Operations Update:
The funding for the AUD 53 million Australian facility has been completed, with physical completion targeted for January 2027 and TGA licensing inspection anticipated by March 31, 2027. Furthermore, the Board approved the incorporation of a US subsidiary, through its Singapore entity, to support the preliminary evaluation of entry into the American market.

SAIPARENT Stock Price Movement​

Sai Parenterals Limited shed 1.28% on Tuesday, with shares settling at ₹573.50 after dropping by ₹7.50 from the previous close. The stock completed its trading day amid high activity, registering a total traded volume of 119,738 shares.